Printer Friendly Version View printer-friendly version
<< Back
Block listing Interim Review
RNS Number : 8539R
Vernalis PLC
29 September 2017
 

BLOCK LISTING SIX MONTHLY RETURN AND BLOCK LISTING APPLICATION

 

VERNALIS PLC (the "Company")

 

29 September 2017

 

Vernalis plc (LSE: VER) provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:

 

Name of applicant:

Vernalis plc

Name of scheme(s):

2007 Long Term Incentive Scheme ("LTIP");

2012 Value Builder Plan ("VBP"); and

2016 Executive Incentive Plan ("EIP")

Period of return (from / to):

From: 29/Mar/2017

To: 29/Sept/2017

Balance of unallotted securities under scheme(s) from previous return:

Total of 728,791 Ordinary 1p Shares, split:

· Under LTIP   =   428,205 Ordinary 1p Shares

· Under EIP     =   300,586 Ordinary 1p Shares

Plus: The amount by which the block scheme(s) has been increased or application has been made to increase since the date of the last return (if any increase has been applied for):

Total of 1,788,674 Ordinary 1p Shares under VBP

As applied for in the below paragraph.

Less: Number of securities issued/allotted under scheme(s) during period:

Total of 78,937 Ordinary 1p Shares under LTIP

Less: Number of securities forfeited under scheme(s) during period:

Total of 10,629 Ordinary 1p Shares, split

· Under LTIP   =   2,426 Ordinary 1p Shares

· Under EIP     =   8,203 Ordinary 1p Shares

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

Total of 2,427,899 Ordinary 1p Shares, split:

· Under LTIP   =   346,842 Ordinary 1p Shares

· Under VBP    =   1,788,674 Ordinary 1p Shares

· Under EIP     =   292,383 Ordinary 1p Shares

Number and class of securities originally admitted and the date of admission (including any additions):

No. of Ordinary 1p Shares

Date on which Shares were Admitted to Trading

350,000

6 November 2013, plus

1,049,317

12 May 2014, plus

1,058,184

12 May 2015, plus

1,638,364

30 September 2015, plus

1,189,296

1 April 2016, plus

499,612

31 March 2017, plus

1,788,674

2 October 2017

 

 

BLOCK LISTING APPLICATION

 

Vernalis plc announces that application has been made to the London Stock Exchange for the admission of 1,788,674 Ordinary Shares of 1 pence each (the "Ordinary Shares") in the Company under the Company's existing block listing scheme. These Ordinary Shares will be available to satisfy future exercises of options over Ordinary Shares under the Company's VBP employee share scheme. It is expected that admission will become effective on 2 October 2017.  When issued, these shares will rank pari passu with the existing Ordinary Shares.

 

-- ends --

 

 

Enquiries:

 

Vernalis plc:

+44 (0) 118 938 0015

Ian Garland, Chief Executive Officer

 

David Mackney, Chief Financial Officer

 

 

Canaccord Genuity Limited (Nominated Adviser and Joint Broker):

+44 (0) 20 7523 8000

Henry Fitzgerald-O'Connor

 

Emma Gabriel

 

 

Shore Capital (Joint Broker):

+44 (0) 20 7408 4090

Bidhi Bhoma

 

Toby Gibbs

 

 

FTI Consulting:

+44 (0) 20 3727 1000

Ben Atwell

 

Simon Conway

 

Stephanie Cuthbert

 

 

 

Notes to Editors

 

About Vernalis

Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development.  The Group has three approved products: Tuzistra® XR, targeting the US prescription cough-cold market; Moxatag®, a once-a-day formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough-cold market as well as eight programmes in its NCE development pipeline.  Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies.  The Company's technologies, capabilities and products have been endorsed over the last ten years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier, and Tris. 

 

For further information about Vernalis, please visit www.vernalis.com 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRLFMMTMBITBIR